Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Pediatric Quality & Safety|February 6, 2025
Improving Adherence to the Lead Exposure Protocol at Boston Medical Center's Pediatric ClinicJulie R Barzilay, Anthony J Mell, MaryKate Driscoll, et al.
Oncotarget|December 22, 2017
Therapeutic effects of the euglenoid ichthyotoxin, euglenophycin, in colon cancerApril B Cabang, Keya De Mukhopadhyay, Sarah Meyers, et al.
Social Science & Medicine (1982)|August 16, 2011
Nothing can defeat combined hands (Abashize hamwe ntakibananira): protective processes and resilience in Rwandan children and families affected by HIV/AIDSTheresa Stichick Betancourt, Sarah Meyers-Ohki, Sara N Stulac, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|December 4, 2012
Validating the Center for Epidemiological Studies Depression Scale for Children in RwandaTheresa Betancourt, Pamela Scorza, Sarah Meyers-Ohki, et al.
Journal of Substance Use and Addiction Treatment|December 9, 2025
A clinical trial loses access to some of its experimental treatment conditions: What can be done?Sarah Meyers-Ohki, Matisyahu Shulman, Roger D Weiss, et al.
Journal of Substance Abuse Treatment|March 28, 2022
A randomized clinical trial of strengths-based case management to link emergency department patients to opioid use disorder treatmentMichael P Bogenschutz, Ryan McCormack, Richard Rapp, et al.
Contemporary Clinical Trials|January 22, 2025
Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD)Matisyahu Shulman, Sarah Meyers-Ohki, Patricia Novo, et al.
Drug and Alcohol Dependence Reports|January 16, 2023
Time-lagged association between counseling and/or 12-Step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorderKathryn Hefner, Tse-Hwei Choo, Dikla Shmueli-Blumberg, et al.
Contemporary Clinical Trials|April 24, 2024
Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trialMatisyahu Shulman, Scott Provost, Kaitlyn Ohrtman, et al.
Hemasphere|February 13, 2025
Single-cell DNA and surface protein characterization of high hyperdiploid acute lymphoblastic leukemia at diagnosis and during treatmentMargo Aertgeerts, Sarah Meyers, Olga Gielen, et al.
Pageof 3